Sangkwang Lee

This inventor holds 7 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignees: Intocell, Inc., Y-Biologics Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sangkwang Lee. Retrieved from https://idiyas.com/inventor/sangkwang-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 6)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 15.6

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12551570 - Compounds comprising cleavable linker and uses thereof (2026-02-17),

2. 12479927 - Compounds comprising cleavable linker and uses thereof (2025-11-25),

3. 12274898 - Substituted benzodiazepines as antibody-drug conjugates (2025-04-14),

4. 12168060 - Antibody-drug conjugates comprising anti-B7-H3 antibodies (2024-12-17),

5. 11807628 - Benzodiazepine derivatives and uses thereof (2023-11-07),

6. 11753431 - Compounds comprising cleavable linker and uses thereof (2023-09-12),

7. 11084801 - Benzodiazepine derivatives and uses thereof (2021-08-10),

Title: The Innovative Contributions of Sangkwang Lee

Introduction

Sangkwang Lee is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of antibody-drug conjugates. With a total of 7 patents to his name, Lee's work has the potential to impact therapeutic approaches in various medical applications.

Latest Patents

Among his latest patents, Lee has developed substituted benzodiazepines as antibody-drug conjugates. This patent provides compounds and compositions that include substituted benzodiazepines of the class of Formula I. Another notable patent involves antibody-drug conjugates comprising anti-B7-H3 antibodies. This disclosure relates to ADCs where one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may include a unit that covalently links active agents to the antibody. Furthermore, the disclosure encompasses monoclonal antibodies and antigen-binding fragments that specifically bind B7-H3, along with methods for their therapeutic, diagnostic, and prophylactic use.

Career Highlights

Sangkwang Lee has worked with several companies throughout his career, including Intocell, Inc. and Y-Biologics Inc. His experience in these organizations has allowed him to refine his expertise in the development of innovative biopharmaceuticals.

Collaborations

Lee has collaborated with notable colleagues such as Taekyo Park and Sung Ho Woo. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Sangkwang Lee's innovative work in the field of antibody-drug conjugates showcases his commitment to advancing medical science. His contributions are poised to make a significant impact on therapeutic strategies in the future.

Profile summary based on public USPTO records.